An interventional study of trans catheter device closure in ASD2(Secundum Atrial Septal Defect), sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
The aim of this study is to evaluate the clinical and echocardiographic influence of dapagliflozin on right ventricular reverse remodeling in adult patients following successful transcatheter Atrial Septal Defect (ASD) device closure.
All patients will be subjected to:
A. Detailed medical history review, clinical evaluation, 12- lead ECG before intervention.
B. Full Laboratory investigations: Preoperative standard Lab Screening: CBC, liver function tests (ALT, AST), coagulation profile, HbA1c, serum creatinine and blood urea nitrogen. The estimated glomerular filtration rate (eGFR) will be calculated using the MDRD or CKD-EPI formula to confirm compliance with the inclusion threshold (≥ 30 mL/min/1.73m²).
C. Echocardiography (TTE):
D. 2D Speckle Tracking Echocardiography ( 2D STE):
- electrocardiographic - gated acquisition of 3- beat loops for standard echocardiographic views, including apical 4 chamber view, apical 2 chamber view, apical 3 chamber view and RV-focused apical 4 chamber view, all obtained in a frame rate between 60- 90 fps [12] for offline analysis.
Left Ventricular (LV) Strain Analysis
o Left Ventricular Global Longitudinal Strain (LVGLS) will be calculated using standard apical 4-chamber, 2-chamber, and 3-chamber views to derive a complete 17-segment peak systolic strain assessment.
Left Atrial (LA) Strain Analysis
o Left Atrial Strain tracking will be conducted on standard, non-foreshortened apical 4-chamber and 2-chamber cine loops optimizing the LA boundaries. [12]
o Phasic Parameter Extraction: Three distinct phasic strain components will be exported from the generated software strain curves: LA Reservoir Strain, LA Conduit Strain, LA Contraction Strain
E. Functional capacity assessment:
- All patients will be classified according to NYHA classification and will undergo 6-Minute Walk Test (6MWT) will evaluate functional distance 12]. also will be evaluated by the Kansas City Cardiomyopathy Questionnaire (KCCQ)
F. Intra- procedural assessment:
In the catheterization laboratory, ASD closure will be performed under general anesthesia guided by TEE to assess the following: ASD anatomy and size, Mitral and tricuspid regurgitation and its degree, Hemodynamics study, assessment of device size, type of the device.
G. Randomization and treatment allocation - Following successful transcatheter closure and stabilization (typically 24-48 hours post-procedure), eligible patients will be randomized in a 1:1 ratio into one of two parallel groups using a manual allocation, sequentially numbered, opaque, sealed envelopes (SNOSE):
o Intervention Group (Dapagliflozin): Patients will receive oral Dapagliflozin 10 mg once daily in addition to standard post-closure medical care (e.g., antibiotics, dual antiplatelet therapy and anti-failure treatment if indicated).
o Control Group: Patients will receive standard post-closure medical therapy alone.
The total planned duration of active pharmacological follow-up is 6 months
H. Follow up of the cases after 3 and 6 months':
All patient with be subjected to the following:
- The functional capacity assessment with the same methods: NYHA Class, 6 WMT distance, KCCQ.
- 1. Adults with ASD and significant left to right shunt which is anatomically suitable for transcatheter device closure.
2. Adults (age ≥18 years) of both genders. 3. Sinus rhythm on presentation.
Exclusion Criteria:
1. Presence of other congenital anomalies e.g. AV canal, CoA, VSDs, PDA, dextrocardia.
2. Significant irreversible pulmonary hypertension (PVR ≥ 5 wood units) or Eisenmenger syndrome.
3. Patients presented with arrythmias (especially atrial fibrillation). 4. Severe left ventricular systolic dysfunction (LV ejection fraction (\< 50%). 5. Significant Valvular Heart Disease. 6. Patients known to have history of ischemic heart disease or percutaneous coronary interventions.
7. Severely impaired renal function defined as an estimated glomerular filtration rate (eGFR) (\< 30 mL/min/1.73m²) 8. Patients with contraindications for SGLT2i: Type 1 diabetes mellitus, history of diabetic ketoacidosis, recurrent severe urinary tract infections, active genital mycotic infections, or known hypersensitivity to dapagliflozin.
9. Poor-quality Echocardiography images precluding strain analysis
given dapagliflozin post ASD closure
Device: trans catheter device closure
given regular treament post ASD closure
Device: trans catheter device closure
randomized clinical trila
RV strain
Assess changes in Right Ventricular Free Wall Longitudinal Strain (RVFWLS) using 2D speckle-tracking echocardiography over a 6-month post-procedural period.
Time frame: follow up after 3 and 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University